In October 2024, AMM traveled to London, England and Amsterdam, Netherlands to meet with regulators from the Medicines & Healthcare products Regulatory Agency (MHRA) and the European Medicines Agency (EMA). AMM members held productive meetings discussing how MHRA and EMA are thinking about platform technology and prior knowledge, the regulatory pathway for future applications of mRNA, including cancer vaccines and gene therapies, how to establish in-country manufacturing with essential CDMOs, and strategies for overcoming vaccine hesitancy and public misconception of RNA-based technologies.
